2025-10786RuleWallet

FDA Gives Fungus-Finding Lung Tests a Less Bureaucratic Path

Published Date: 6/13/2025

Rule

Summary

The FDA is officially putting devices that detect fungal DNA in lung samples into a safer, easier-to-manage category called Class II. This change helps make sure these devices work well and are safe, while also speeding up patient access to new tech by cutting red tape. The new rules took effect on June 13, 2025, and could save companies time and money by simplifying approval steps.

Analyzed Economic Effects

3 provisions identified: 2 benefits, 1 costs, 0 mixed.

Reclassified fungal-DNA lung tests to Class II

The FDA officially classified devices that detect and identify fungal nucleic acids directly in respiratory specimens as Class II (special controls), effective June 13, 2025 (classification applicable November 29, 2017). The agency says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access to these diagnostic tests by reducing regulatory burdens.

Easier regulatory path for future devices

Because the device was classified into Class II via the De Novo process, it can serve as a predicate device for future devices of the same type, allowing other sponsors to use the 510(k) premarket notification pathway instead of De Novo or premarket approval; the FDA says this reduces regulatory burdens and can speed access to new devices.

New special-control testing and labeling rules for manufacturers

Manufacturers of these fungal-nucleic-acid respiratory tests must meet Class II special controls in labeling and design verification/validation. Labeling must include detailed device description, instrument requirements, ancillary reagents, methodology, analytical performance data (including limit of detection, inclusivity, reproducibility, interference, cross-reactivity, carryover/cross-contamination, and specimen stability), interpretation guidance, and a statement that negative results do not rule out infection. Clinical and analytical validation must include prospective clinical studies with predefined statistical plans and documentation of device software and data-processing methods.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
6/13/2025
6/13/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register